| Dr David Leo Kipps, MD | |
|
700 Frederick St Ste 203, Santa Cruz, CA 95062 | |
| (831) 425-1906 | |
| (831) 469-8764 |
| Full Name | Dr David Leo Kipps |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Pulmonary Disease |
| Location | 700 Frederick St Ste 203, Santa Cruz, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972510048 | NPI | - | NPPES |
| GR0056730 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | G33598 (California) | Primary |
| 207RC0200X | Internal Medicine - Critical Care Medicine | G33598 (California) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Leo Kipps, MD 700 Frederick St Ste 203, Santa Cruz, CA 95062 Ph: (831) 425-1906 | Dr David Leo Kipps, MD 700 Frederick St Ste 203, Santa Cruz, CA 95062 Ph: (831) 425-1906 |
News Archive
Current hospital cleaning protocol may be inadequate to rid patient rooms of multidrug-resistant (MDR) Acinetobacter baumannii, according to a study in the December issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).
A paper published today in Science Translational Medicine describes a simple, minimally invasive new tool for viewing differences in the nasal airways of cystic fibrosis patients in vivo at a cellular level.
Boston Scientific Corporation today announced U.S. Food and Drug Administration approval of two spinal cord stimulation (SCS) leads for use with its Precision Plus™ Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk and/or limbs. The Linear™ 3-4 and Linear™ 3-6 Percutaneous Leads offer wider contact spacing to expand the lead choices available to physicians. The Company plans to launch the products immediately in the U.S.; they were launched in Europe and other international markets earlier.
› Verified 3 days ago
Nicole Sudduth, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 115 Locust St, Santa Cruz, CA 95060 Phone: 831-458-5670 | |
Timothy W Allari, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2025 Soquel Ave, Santa Cruz, CA 95062 Phone: 831-458-5610 | |
Brent Culver, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2025 Soquel Ave, Santa Cruz, CA 95062 Phone: 831-458-5577 | |
Holly B Moore, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2025 Soquel Ave, Santa Cruz, CA 95062 Phone: 831-458-5610 Fax: 831-423-6410 | |
Pritisheel Banga, DO Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1595 Soquel Dr Ste 411, Santa Cruz, CA 95065 Phone: 831-475-8834 Fax: 831-462-2058 | |
Michael Alexander, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1669 Dominican Way, Santa Cruz, CA 95065 Phone: 831-475-2220 Fax: 831-475-2221 | |
Dr. James L Poth Jr., MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 419 Carbonera Dr, Santa Cruz, CA 95060 Phone: 831-426-0607 Fax: 831-427-1525 |